Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Guidance Coming for Anticipated COVID-19 Vaccine

Carina Stanton  |  September 4, 2020

As the world anxiously awaits a COVID-19 vaccine, rheumatology providers are equally anxious to understand the efficacy and safety of the vaccines under study, as well as how a new vaccine will be allocated.

To provide guidance for these and other COVID-19 vaccine-related questions, the ACR’s COVID-19 Practice & Advocacy Task Force, comprising rheumatologists, pharmacists, office managers and psychologists, is developing a guidance document related to an anticipated vaccine, according to task force chair Kelly Weselman, MD, a rheumatologist in the WellStar Medical Group, Atlanta.

Dr. Kelly Weselman

Staying a Step Ahead
Guidance for a COVID-19 vaccine will be the latest in a series of resource documents released by the task force to respond to the almost daily changes and needs emerging from the pandemic, whether they are changes based on access issues to medications, such as hydroxychloroquine, or emerging developments related to telehealth and economic support for practices.

As of Sept. 1, the task force has released more than 30 guidance documents, FAQs and videos providing guidance to support practicing rheumatologists and their patients through COVID-19. 

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

To provide rapid response to emerging issues, the ACR formed the COVID-19 Practice & Advocacy Task Force and a COVID-19 Clinical Task Force in late March as the first wave of the COVID-19 crisis hit the U.S. . Ever since, the COVID-19 Practice & Advocacy Task Force members have been fielding questions coming into the ACR and taking input from focus groups to best address members’ COVID-19 concerns and questions.

“Our charge has been to help members respond rapidly to changes in clinical practice during COVID-19 in order to serve our patients better. We’ve worked every day to identify the needs of members and develop the resources to help them,” Dr. Weselman says.

ACR staff members have supported task force members in this work by sharing resources for telehealth, connecting with the U.S. Food & Drug Administration regarding issues related to hydroxychloroquine and staying on top of the latest information on funding from the Public Health and Social Services Emergency Fund in the Coronavirus Aid, Relief and Economic Security (CARES) Act to help practices survive.

Supporting Ongoing Challenges
The main concerns ACR members have shared during the pandemic have been around telehealth, financial practice support and access to such medications as hydroxychloroquine.

To provide easy access to information to support these and other concerns, all COVID-19 Practice & Advocacy Task Force guidance documents are posted on the task force webpage. Resources are divided into four topic areas: telehealth, practice support, economic support and insurance advocacy. Here’s a snapshot of several resources in each category:

Page: 1 2 | Single Page
Share: 

Filed under:Legislation & AdvocacyPractice Support Tagged with:COVID-19COVID-19 Practice & Advocacy Task ForceDr. Kelly Weselman

Related Articles

    The End of the Beginning: COVID-19 Vaccines & Other Conundrums

    December 9, 2020

    “It’s like winning Powerball.” For months, there has been a steady trickle of questions from my patients, asking for my opinion about the new vaccines being developed to prevent COVID-19. More to the point, they want to know if they should be vaccinated. ad goes here:advert-1ADVERTISEMENTSCROLL TO CONTINUEAfter some fits and starts, I finally struck…

    Vaccine Hesitancy: Wariness Is Rare, But There’s a Wider Worry About COVID Vaccines’ Efficacy in Some Populations

    July 6, 2021

    Hesitancy about COVID-19 vaccination persists nationwide, although it varies among regions and sociodemographic groups.

    Vax Hesitancy? Myths & Facts for Patients

    December 16, 2021

    Although more than 189,300,000 eligible Americans are fully vaccinated against SARS-CoV-2 as of Oct. 18, 2021, vaccine hesitancy persists.1 The U.S. Centers for Disease Control and Prevention (CDC), citing data from the U.S. Census Bureau’s Household Pulse Survey collected between May 26 and June 7, 2021, reports that in some U.S. counties—particularly in the Southeast…

    Anze Furlan / SHUTTERSTOCK.COM

    How Immunosuppression May Affect COVID-19 Vaccine Response

    June 13, 2021

    Although we can expect to learn much more, preliminary data are now available on the potential safety and effectiveness of COVID-19 vaccines in rheumatology patients. The picture is likely to be nuanced, with not all types of immuno­suppressive treatments having identical impacts on vaccine response. Rheumatologists should use caution in interpreting early reports, while continuing…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences